Meital Portugal
Seminars
Wednesday 20th May 2026
Roundtable Discussion: Strategic Selection of the First Validation Indication for Novel Biologic Formats
11:30 am
- How emerging biologic formats (nanobodies, bispecifics, multi-pathway antibodies) change the logic of indication selection
- When crowded indications like psoriasis or AD make sense as platform-validation settings rather than commercial endpoints
- Trade-offs between rare diseases and common diseases as first-in-human or first-proof-of-concept opportunities
- What level and type of early data regulators and pharma partners actually need to believe in a platform
- Balancing scientific elegance, capital efficiency, CMC risk, and partnering attractiveness in early development decisions
